ClinicalTrials.gg

Program

OM336

A development code.

Its studies are mostly in Anemia, Hemolytic, Autoimmune · Myositis, led by Lakefront Biotherapeutics NV.

Furthest: phase 1, since Jul 9, 20252 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lakefront Biotherapeutics NV22 open or runningphase 1since Jul 9, 2025Jul 9, 2025Dec 2026phase 1 · NCT07083960

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 9, 2025First study: phase 1 study in Anemia, Hemolytic, AutoimmuneFirst studyNCT07083960 · 32 planned · United States, Australia
  2. Nov 13, 2025Phase 1 study in MyositisNCT07229144 · 39 planned · New Zealand

Ahead

  1. Dec 2026Primary completion: phase 1 study in Anemia, Hemolytic, AutoimmuneNCT07083960
  2. Jun 2027Primary completion: phase 1 study in MyositisNCT07229144

TargetBeta

CD3E →read by rule
“OM336 is an engineered bispecific antibody directed against BCMA and CD3”study text, by rule · the study

Other programs on CD3E

ProgramCompanyFurthest phaseStudies
etentamigAbbViephase 311
obrixtamigBoehringer Ingelheimphase 311
surovatamigAstraZenecaphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
cevostamabHoffmann-La Rochephase 38
ramantamigJohnson & Johnsonphase 37
pasritamigJohnson & Johnsonphase 35
TQB2825Sino Biopharmaceuticalphase 35
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
gocatamigMerckphase 34
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 22

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07229144Myositis · New Zealand1RecruitingJun 202739
NCT07083960Anemia, Hemolytic, Autoimmune · United States, Australia1RecruitingDec 202632

How it is read

Names in the registry

  • “OM336”, 2 entries

Codes read as this program: OM336.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.